KRAS and non-small cell lung carcinoma: Notably, phase 1 studies on D1553 (garsorasib) and GDC6034 (divarasib) have been published; D1553 and GDC6034 were administered to 79 patients with KRAS G12C-mutated non-small cell lung cancers (NSCLCs) and 137 patients (60 with NSCLCs, 55 with colorectal cancer, and 22 with other solid tumors), respectively.